Cargando…
Diagnostic impact of [(18)F]flutemetamol PET in early-onset dementia
BACKGROUND: Early-onset dementia patients often present with atypical clinical symptoms, hampering an accurate clinical diagnosis. The purpose of the present study was to assess the diagnostic impact of the amyloid-positron emission tomography (PET) imaging agent [(18)F]flutemetamol in early-onset d...
Autores principales: | Zwan, Marissa D., Bouwman, Femke H., Konijnenberg, Elles, van der Flier, Wiesje M., Lammertsma, Adriaan A., Verhey, Frans R. J., Aalten, Pauline, van Berckel, Bart N. M., Scheltens, Philip |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5240413/ https://www.ncbi.nlm.nih.gov/pubmed/28093088 http://dx.doi.org/10.1186/s13195-016-0228-4 |
Ejemplares similares
-
Assessing Amyloid Pathology in Cognitively Normal Subjects Using (18)F-Flutemetamol PET: Comparing Visual Reads and Quantitative Methods
por: Collij, Lyduine E., et al.
Publicado: (2019) -
Clinical outcomes up to 9 years after [(18)F]flutemetamol amyloid-PET in a symptomatic memory clinic population
por: Collij, Lyduine E., et al.
Publicado: (2023) -
Discordant amyloid-β PET and CSF biomarkers and its clinical consequences
por: de Wilde, Arno, et al.
Publicado: (2019) -
PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases
por: Reimand, Juhan, et al.
Publicado: (2019) -
Added value of amyloid PET in individualized risk predictions for MCI patients
por: van Maurik, Ingrid S., et al.
Publicado: (2019)